ANXA1 ‐Derived Peptide Increases Melanoma Cell Sensitivity to Vemurafenib by Downregulating EphA2
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Juan Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Vemurafenib, Melanoma, Receptor, EphA2, Down-Regulation. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Scientific Research Fund of Hunan Provincial Education Department.
Abstract (Originalsprache)
Vemurafenib (VEM) is a BRAF inhibitor that improves the prognosis of melanoma, but acquired resistance represents a key limitation to its clinical efficacy. This study investigated the potential of A11, an Annexin A1 (ANXA1)‐derived peptide, to enhance VEM efficacy in both VEM‐sensitive and VEM‐resistant melanoma cells. We evaluated the effects of A11 in melanoma through in vitro assays (including MTT, clonogenic survival, apoptosis, and cell cycle analysis) and in vivo xenograft models in nude mice. Furthermore, we mechanistically interrogated A11‐mediated suppression of EphA2 expression and the downstream pS897‐EphA2/AKT/ERK signalling pathway in resistant and parental cell lines via Western blotting and immunohistochemistry (IHC). Critically, our study demonstrates that A11 inhibits melanoma cell proliferation and reverses VEM resistance through EphA2 downregulation, consequently ablating this oncogenic pathway. This research highlights the promising application value of A11 in improving the efficacy of VEM treatment in melanoma, particularly in VEM‐resistant melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- The Higher Educational Key Laboratory for Cancer Proteomics and Translational Medicine of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oncology, Xiangtan Central Hospital, Xiangtan, Hunan, China.
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Juan Feng, Xiao-Pu Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Scientific Research Fund of Hunan Provincial Education Department
- Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University.
Zitieren
APA
Feng, J., Huang, X. P., Zhang, M., Huang, W., Lu, S. S., Xiao, Z. Q., Xie, Z. H., & Yi, H. (2026). ANXA1 ‐Derived Peptide Increases Melanoma Cell Sensitivity to Vemurafenib by Downregulating EphA2. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71310
Vancouver
Feng J, Huang XP, Zhang M, Huang W, Lu SS, Xiao ZQ, et al. ANXA1 ‐Derived Peptide Increases Melanoma Cell Sensitivity to Vemurafenib by Downregulating EphA2. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71310
BibTeX
@article{Feng2026,
author = {Feng, Juan and Huang, Xiao-Pu and Zhang, Ming and Huang, Wei and Lu, Shan-Shan and Xiao, Zhi-Qiang and Xie, Zhi-Hai and Yi, Hong},
title = {ANXA1 ‐Derived Peptide Increases Melanoma Cell Sensitivity to Vemurafenib by Downregulating EphA2},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71310}
}
EUVIMED